THREE NAMES, ONE FORMULATION

RetaBone, Rethiamine and Reta-B1: one formulation

RetaBone™ is Rethiamine. Not a similar formulation, not a related one — the same proprietary Panacea Bio Chem research formulation, under a different scientific lens. Three names. Three research perspectives. One formulation.

All three describe the same proprietary Panacea Bio Chem formulation: a 5 mg retatrutide lower layer and a 20 mg thiamine upper layer, co-lyophilised as a dual-layer Peptourbillon™ in Lyoprester SS™ and reconstituted by 0.5 mL P-EARLs™.

The Lyoprester SS dual-chamber single-shot device that holds the shared Rethiamine formulation: protected lyophilised chamber beside the separate 0.5 mL P-EARLs reconstitution chamber — The Lyoprester SS™ device — the single dual-chamber platform all three identities describe.

Rethiamine™ is the product and formulation identity — the definitive source for what the formulation is, its architecture and its development status: Rethiamine retatrutide and thiamine formulation ↗. Reta-B1™ is the thiamine and technical evidence identity: Reta-B1 technical evidence hub ↗. RetaBone™ — this site — is the body-composition and metabolic-resilience identity, covering lean mass, muscle, bone-health research and nutritional resilience.

The delivery architecture is documented at the Lyoprester SS single-shot platform ↗ site, and the developer at Panacea Bio Chem proprietary formulation ↗. For what RetaBone adds on top of the shared formulation, see what is RetaBone? and the research agenda.